NASDAQ:CMMB Chemomab Therapeutics Q1 2026 Earnings Report $2.05 -0.02 (-0.96%) As of 11:27 AM Eastern ProfileEarnings HistoryForecast Chemomab Therapeutics EPS ResultsActual EPS-$0.22Consensus EPS -$0.04Beat/MissMissed by -$0.18One Year Ago EPSN/AChemomab Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AChemomab Therapeutics Announcement DetailsQuarterQ1 2026Date5/14/2026TimeBefore Market OpensConference Call DateThursday, May 14, 2026Conference Call Time8:00AM ETUpcoming EarningsChemomab Therapeutics' Q2 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedulesConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) Chemomab Therapeutics Earnings HeadlinesChemomab Therapeutics Ltd.: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 19 at 10:38 PM | finanznachrichten.deChemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 19 at 8:26 AM | globenewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.August 21 at 1:00 AM | Banyan Hill Publishing (Ad)Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks TranscriptJuly 8, 2026 | seekingalpha.comChemomab to merge with Scipher MedicineJuly 8, 2026 | msn.comChemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid ArthritisJuly 8, 2026 | globenewswire.comSee More Chemomab Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Chemomab Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chemomab Therapeutics and other key companies, straight to your email. Email Address About Chemomab TherapeuticsChemomab Therapeutics (NASDAQ:CMMB) (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development. Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes. Its lead oncology programs employ novel bispecific formats intended to engage immune effector cells against solid tumors, while infectious disease programs focus on broad-spectrum neutralization of viral pathogens. Chemomab’s inflammatory disease efforts seek to modulate autoimmune pathways through highly selective receptor blockade. Headquartered in Shanghai with a presence in the United States, Chemomab fosters global collaboration with academic institutions and contract research organizations. The company was founded by a team of immunology and protein engineering experts and is led by a management group with extensive experience in biotechnology R&D and regulatory affairs. Through strategic partnerships and disciplined clinical development, Chemomab Therapeutics is positioning itself to address significant unmet medical needs in multiple therapeutic areas.View Chemomab Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Microsoft's Sell-Off May Be a Gift, Not a WarningIs Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?Advance Auto Parts Plunged, But Its Turnaround Is Still WorkingWalmart's Post-Earnings Drop Could Be a Buying Opportunity3 Energy Stocks Raising Dividends as the Sector Surges5 Reasons the S&P 500 Could Keep Rallying Through Year-EndMeta Platform's Legal Issues Could Become Much More Than A Q2 Earnings Headache Upcoming Earnings PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
